Integra LifeSciences Holdings Corporation (IART)

Market Cap	1.68B
Revenue (ttm)	1.56B
Net Income (ttm)	-6.55M
Shares Out	77.16M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	8.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,114,256
Open	21.48
Previous Close	21.71
Day's Range	21.31 - 22.29
52-Week Range	16.81 - 45.42
Beta	1.16
Analysts	Sell
Price Target	24.67 (+13.17%)
Earnings Date	Nov 4, 2024

About IART

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and ins...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Aug 16, 1995
• Employees: 3,946
• Stock Exchange: NASDAQ
• Ticker Symbol: IART
• Website: https://www.integralife.com

Financial Performance

In 2023, IART's revenue was $1.54 billion, a decrease of -1.03% compared to the previous year's $1.56 billion. Earnings were $67.74 million, a decrease of -62.48%.

Analyst Forecast

According to 7 analysts, the average rating for IART stock is "Sell." The 12-month stock price forecast is $24.67, which is an increase of 13.17% from the latest price.

Price Target

$24.67

(13.17% upside)

Analyst Consensus: Sell